title: Mutations in the putative HCV-E2 CD81 binding regions and correlation with cell surface CD81 expression.
abstract: The hepatitis C virus (HCV) envelope (E)2 protein interacts with the cellular receptor CD81 leading to modulation of B and T cell function. Recently, a higher binding affinity of subtype 1a in comparison with 1b derived E2 proteins for CD81 in vitro was described. The importance of mutations within the putative CD81 binding regions of different HCV geno-/subtypes in correlation with CD81 expression is unknown. In the present study, CD81 expression on blood lymphocytes of patients with chronic hepatitis C infected with different HCV geno-/subtypes were analysed by fluorescence activated cell sorter analyses. In addition, the putative CD81 binding regions on the E2 gene comprising the hypervariable region (HVR)2 were analysed by direct sequencing. CD81 expression on CD8(+) T-lymphocytes from patients infected with subtype 1a (n = 6) was significantly higher in comparison with subtype 1b (n = 12) and 3 (n = 5) infected patients before and during antiviral therapy (P = 0.006; P = 0.021, respectively). Sequencing of the putative CD81 binding regions in the E2 protein comprising the HVR2 (codon 474-495 and 522-552 according to the HCV-1a prototype HCV-H) showed a highly conserved motif within HVR2 for subtype 1a isolates and an overall low number of mutations within the putative CD81 binding regions, whereas numerous mutations were detected for subtype 1b isolates (12.0 vs 23.6%). HCV-3 isolates showed an intermediate number of mutations within the putative binding sites (19.2%; P = 0.022). In conclusion, the highly conserved sequence within HVR2 and putative CD81 binding sites of subtype 1a isolates previously associated with a high CD81 binding affinity in vitro is correlated with high CD81 expression on CD8(+) T-lymphocytes in vivo.
authors.affiliation: Klinik für Innere Medizin II, Universitätsklinikum des Saarlandes, Homburg/Saar, Germany.
authors.forename: B
authors.initials: B
authors.lastname: Kronenberger
authors.forename: C
authors.initials: C
authors.lastname: Sarrazin
authors.forename: W P
authors.initials: WP
authors.lastname: Hofmann
authors.forename: M
authors.initials: M
authors.lastname: von Wagner
authors.forename: E
authors.initials: E
authors.lastname: Herrmann
authors.forename: C
authors.initials: C
authors.lastname: Welsch
authors.forename: R
authors.initials: R
authors.lastname: Elez
authors.forename: B
authors.initials: B
authors.lastname: Rüster
authors.forename: A
authors.initials: A
authors.lastname: Piiper
authors.forename: S
authors.initials: S
authors.lastname: Zeuzem
mesh_terms: D000328:Adult; D000368:Aged; D000595:Amino Acid Sequence; D015703:Antigens, CD / Q000032:analysis*; D001665:Binding Sites; D018414:CD8-Positive T-Lymphocytes / Q000378:metabolism*; D005260:Female; D005434:Flow Cytometry; D015870:Gene Expression; D005838:Genotype; D016174:Hepacivirus / Q000235:genetics* / Q000302:isolation & purification; D019698:Hepatitis C, Chronic / Q000276:immunology / Q000821:virology*; D006801:Humans; D008297:Male; D008875:Middle Aged; D008969:Molecular Sequence Data; D009154:Mutation; D011485:Protein Binding; D011991:Receptors, Virus / Q000032:analysis; D017421:Sequence Analysis; D060225:Tetraspanin 28; D014759:Viral Envelope Proteins / Q000235:genetics*
chemical_list: D015703:Antigens, CD; C554798:CD81 protein, human; D011991:Receptors, Virus; D060225:Tetraspanin 28; D014759:Viral Envelope Proteins; C091015:glycoprotein E2, Hepatitis C virus